SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

BLASCO VALLE, M.; TIMON GARCIA, A.  y  LAZARO MUNOZ, V.. Abordaje de la hiperplasia benigna de próstata: Actuación Atención Primaria-Especializada. Medifam [online]. 2003, vol.13, n.3, pp.13-22. ISSN 1131-5768.

    1. Hunter DJW, Berra-Unamuno A, Martín-Gordo A. Prevalence of urinary syntoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996; 155: 1965-8.  [ Links ]


    2. Jiménez Cruz F. Presentación. En: Vicente R, J. HBP 2001. Hiperplasia Benigna de Próstata. Madrid: Ed. Acción Médica, 2002. p. 5.  [ Links ]


    3. Holtgrewe HL. Transurethral prostatectomy. Urol Clin North Am 1995; 22: 357-68.  [ Links ]


    4. Burgos Rodríguez R, Chicharro Molero JA. Hiperplasia Benigna de Próstata. En: Jiménez Cruz JF, Rioja Sanz LA. Tratado de Urología. Barcelona: Ed. J.R. Prous, 1993. p. 1035-50.  [ Links ]


    5. Resel L, Vela R, Conejero J, Jiménez Cruz, Vicente J, Rioja LA. Hiperplasia benigna de próstata. Bases diagnósticas y terapéuticas. Madrid: Ed. Enar, 1993.  [ Links ]


    6. Lepor, Lawson. Enfermedades de la próstata. Buenos Aires: Ed. Panamericana, 1994.  [ Links ]


    7. Hernández C, Moncada I. Hiperplasia benigna de próstata. Madrid: Ed. Luzán, 1999.  [ Links ]


    8. Carballido JA, Rodríguez J, Llano J. Hiperplasia prostática benigna y medicina basada en la evidencia. Med Clin (Barc) 2000; 114 (Supl. 2): 96-104S.  [ Links ]


    9. Barry MJ, Wiiliford WO, Fowler FJ. American Urological Association Symptom index: The value of their distinction in a Veterans Affairs randomised trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. J Urol 2000; 164: 1559-64.  [ Links ]


    10. Castro Díaz D, Postius Robert J. Urología en AP. Barcelona: Ed. Pulso, 2001.  [ Links ]


    11. Bedós F, Cibert J. Adenoma de próstata. En: Urología. La terapéutica y sus bases. Barcelona: Espaxs ed., 1989. p. 997-1048.  [ Links ]


    12. Morote J, Ruibal A, Pont A. Valor del antígeno prostático específico en la predicción del cáncer prostático. Actas Urol Esp 1988; 12: 10-4.  [ Links ]


    13. Jiménez Cruz JF, Rodríguez Vallejo JM, López Solsona A, Frías Jimeno S. Los médicos de Atención Primaria y la patología prostática. Encuesta nacional. Actas Urológicas Españolas 1996. p. 624-9.  [ Links ]


    14. Laguna P, Alivizatos G. Antígeno prostático específico e hiperplasia prostática benigna. Curr Opin Urol 2000; 10: 3-8.  [ Links ]


    15. Denis L, McConnell J, Yoshida O, Khoury S, Abrams P, Barry M, et al. Recommendations of the International Scientific Committee: The Evaluation and Treatment of Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Obstruction. En: Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O. 4th International Consultation on Benign Prostatic Hyperplasia (BPH). París: Ed. SCI, 1998. p. 674.  [ Links ]


    16. Bosch R, Donovan J, Okada K. Symptons evaluation, quality of life and sexuality. I-PSS. The 2nd international consultation on benign prostatic hyperplasia proceedings. En: Cockett AT, Aso Y, Chatelain C (eds). SCI. 1993. p. 131-143.  [ Links ]


    17. Postius J, Castro D. Tratamiento farmacológico de la HBP basado en la evidencia. Rev Clin Esp 1999; 199 (2): 58-61.  [ Links ]


    18. Vergeles-Blanca JM, Pozuelos G, Buitrago F. Controversias en el tratamiento de la hiperplasia benigna de próstata. FMC- Formación Médica Continuada en Atención Primaria 1996: 215.  [ Links ]


    19. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double bind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 1995; 1529-32.  [ Links ]


    20. Wilt TJ, Ishani A, Stark G, MacDonald R, Mulrow C, Sau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000; 2: CD001423.  [ Links ]


    21. Cockett ATK. The 3rd International Consultation on Benign Prostatic Hyperplasia (BHP). World Health Organization. Mónaco 1995.  [ Links ]


    22. World Health Organization Fourth International Consultation on Benign Prostatic Hyperplasia. Procedingss. Paris 1997.  [ Links ]


    23. Lepor H. The treatment of benign prostatic hyperplasia with alpha-1-blockers. Curr Opin Urol 1994; 4: 16-21.  [ Links ]


    24. Pool JL. Effects of doxazosin on serum lipids. A review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991; 121: 251.  [ Links ]


    25. Christensen M, Bendix Holme J, Rassmunsen PC. Doxazosin treatment in patients with prostate obstruction. Scand J Urol 1993; 27: 39.  [ Links ]


    26. Abrams P, Schulman CC, Vaage S. European Tamsulosin Study Group. Tamsulosin a selective alpha-1c adrenoreceptor antagonist. Br J Urol 1995; 76: 325.  [ Links ]


    27. Finasteride Study Group. Finasteride in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 91.  [ Links ]


    28. Mc Connell JD, Bruskwitz R, Walsh P, Adriole G, Lieber M, Holtgrewe L, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med 1998; 338: 557-63.  [ Links ]


    29. Mebust WK. Selection of the surgical procedure for management of benign prostatic hyperplasia. Prog Clin Biol Res 1994; 386: 369-84.  [ Links ]


    30. Errando C, Laguna P, Salvador J, Vicente J. Litotricia endoscópica mediante Lithoclast. Arch Esp Urol 1995; 48: 621-4.  [ Links ]


    31. Lepor H, Rigaud G. The efficacy of transurethral resention of the prostate in men with moderate symptoms of prostatism. J Urol 1990; 143: 533-7.  [ Links ]


    32. Fowler FJ. Patient reports of symptoms and quality of life following prostate surgery. Eur Urol 1991; 20 (Supl. 1): 44-9S.  [ Links ]


    33. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999; 83: 227-37.  [ Links ]


    34. Perkins JB, Miller HC. Blood loss during transurethral prostatectomy. J Urol 1969; 101: 93-7.  [ Links ]


    35. Uchida T, Ohori M, Soh S. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. J Urol 1999; 53: 98-195.  [ Links ]


    36. Horninger W, Unterlechner H, Strasser H, Bartsch G. Transurethral prostatic resection: mortality and morbidity. Prostate 1996; 28: 195-200.  [ Links ]


    37. Orandi A. Urological endoscopic surgery under local anesthesia: a cost-reducing idea. J Urol 1984; 132: 1142-6.  [ Links ]


    38. Loughlin KR, Yalla SU, Belldegaunt GT. Transurethral incision and resection under local anesthesia. J Urol 1987; 60: 185-7.  [ Links ]


    39. Soler Roselló A, Vila J, Conejero J, Sarrias F, Ahmad A, Reig C. Trigonocervicoprostatotomías. Arch Esp Urol 1991; 44: 601-9.  [ Links ]


    40. Soonawalla PF, Pardanani DS. Transurethral incision versus transurethral resection of the prostate. A subjective and objective analysis. Br J Urol 1992; 70: 174-7.  [ Links ]


    41. Vicente J, Sánchez-Martín F, Palou J. Resección versus incisión transuretral en la HBP. Valoración crítica. Arch Esp Urol 1994; 47: 915-24.  [ Links ]


    42. Stromaier B, Bichler K, Fluchter S. Local microwave hypertermia of benign prostatic hyperplasia. J Urol 1990; 144: 913-7.  [ Links ]


    43. Linder A, Braf F, Lev A. Local hypertermia of the prostate gland for the treatment of benign prostatic hypertrophy and urinary retention. Br J Urol 1990; 65: 201-3.  [ Links ]


    44. Krawitz DR, Addonizio JC. Ultrasonic aspiration of prostate, bladder tumors and stones. Urology 1987; 30: 579-80.  [ Links ]


    45. Malloy T, Carpinello V, Wein A. Bladder outlet treated with transurethral ultrasonic aspiration. Urology 1991; 37: 412-515.  [ Links ]


    46. Sigwart U, Puel, Mirkovitch V. Intravascular stents prevent occlusion and restenosis after transluminal angioplasty. N Engl Med 1987; 316: 701-6.  [ Links ]


    47. Milroy EJ, Cooper JE, Wallsten H. A new treatment for urethral strictures. Lancet 1988; 25: 1424-7.  [ Links ]


    48. Milroy EJ, Chapple CR, Eldin A. A new stent for the treatment of urethral strictures. Preliminary report. Brit J Urol 1989; 63: 392-6. [ Links ]


    49. Parra R, Boullier J, Cummings J. Endoluminal Urethra Stent: a review. J Endourol 1993; 7: 117-23.  [ Links ]


    50. Russinovich NA, Lloyd LR, Griggs WP. Balloon dilatation of urethral strictures Urol Radiol 1980; 2: 33-37. [ Links ]


    51. Fishman IJ. Experience with hydraulic balloon urethral dilator for office on self-dilatation. J Urol 1992; 147: 287-90. [ Links ]


    52. Nielsen T, Moore RG, Alfert HJ. Alternative endoscopic management in the treatment of urethral strictures. J Endourol 1995; 9: 31-9. [ Links ]